دورية أكاديمية
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
| العنوان: | Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study |
|---|---|
| المؤلفون: | Carmona-bayonas, Alberto, Jiménez-fonseca, Paula, Lamarca, Ángela, Barriuso, Jorge, Castaño, Ángel, Benavent, Marta, Alonso, Vicente, Riesco-martínez, María Del Carmen, Alonso-gordoa, Teresa, Custodio, Ana, Sánchez Cánovas, Manuel, Hernando Cubero, Jorge, López, Carlos, Lacasta, Adelaida, Fernández Montes, Ana, Marazuela, Mónica, Crespo, Guillermo, Escudero, Pilar, Diaz, José Ángel, Feliciangeli, Eduardo, Gallego, Javier, Llanos, Marta, Segura, Ángel, Vilardell, Felip, Percovich, Juan Carlos, Grande, Enrique, Capdevila, Jaume, Valle, Juan W., García-carbonero, Rocío |
| المصدر: | Carmona-bayonas , A , Jiménez-fonseca , P , Lamarca , Á , Barriuso , J , Castaño , Á , Benavent , M , Alonso , V , Riesco-martínez , M D C , Alonso-gordoa , T , Custodio , A , Sánchez Cánovas , M , Hernando Cubero , J , López , C , Lacasta , A , Fernández Montes , A , Marazuela , M , Crespo , G , Escudero , P , Diaz , J Á , Feliciangeli , E , Gallego , J , Llanos , M , Segura , Á , Vilardell .... |
| سنة النشر: | 2019 |
| المجموعة: | The University of Manchester: Research Explorer - Publications |
| مصطلحات موضوعية: | somatostatin analogs, lanreotide, neuroendocrine tumors, nomogram, octreotide, prognostic model, progression-free survival, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre |
| الوصف: | PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. PATIENTS AND METHODS We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom). RESULTS We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively. CONCLUSION The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1200/JCO.19.00980 |
| الإتاحة: | https://doi.org/10.1200/JCO.19.00980Test https://research.manchester.ac.uk/en/publications/d2d3b527-1f1d-4af6-996b-0761cc39e363Test https://pure.manchester.ac.uk/ws/files/121181372/jco.19.00980.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.EE077A56 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.EE077A56 904 3 Academic Journal academicJournal 903.687927246094 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.EE077A56&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1200/JCO.19.00980# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Carmona-bayonas%2C+Alberto%22">Carmona-bayonas, Alberto</searchLink><br /><searchLink fieldCode="AR" term="%22Jiménez-fonseca%2C+Paula%22">Jiménez-fonseca, Paula</searchLink><br /><searchLink fieldCode="AR" term="%22Lamarca%2C+Ángela%22">Lamarca, Ángela</searchLink><br /><searchLink fieldCode="AR" term="%22Barriuso%2C+Jorge%22">Barriuso, Jorge</searchLink><br /><searchLink fieldCode="AR" term="%22Castaño%2C+Ángel%22">Castaño, Ángel</searchLink><br /><searchLink fieldCode="AR" term="%22Benavent%2C+Marta%22">Benavent, Marta</searchLink><br /><searchLink fieldCode="AR" term="%22Alonso%2C+Vicente%22">Alonso, Vicente</searchLink><br /><searchLink fieldCode="AR" term="%22Riesco-martínez%2C+María+Del+Carmen%22">Riesco-martínez, María Del Carmen</searchLink><br /><searchLink fieldCode="AR" term="%22Alonso-gordoa%2C+Teresa%22">Alonso-gordoa, Teresa</searchLink><br /><searchLink fieldCode="AR" term="%22Custodio%2C+Ana%22">Custodio, Ana</searchLink><br /><searchLink fieldCode="AR" term="%22Sánchez+Cánovas%2C+Manuel%22">Sánchez Cánovas, Manuel</searchLink><br /><searchLink fieldCode="AR" term="%22Hernando+Cubero%2C+Jorge%22">Hernando Cubero, Jorge</searchLink><br /><searchLink fieldCode="AR" term="%22López%2C+Carlos%22">López, Carlos</searchLink><br /><searchLink fieldCode="AR" term="%22Lacasta%2C+Adelaida%22">Lacasta, Adelaida</searchLink><br /><searchLink fieldCode="AR" term="%22Fernández+Montes%2C+Ana%22">Fernández Montes, Ana</searchLink><br /><searchLink fieldCode="AR" term="%22Marazuela%2C+Mónica%22">Marazuela, Mónica</searchLink><br /><searchLink fieldCode="AR" term="%22Crespo%2C+Guillermo%22">Crespo, Guillermo</searchLink><br /><searchLink fieldCode="AR" term="%22Escudero%2C+Pilar%22">Escudero, Pilar</searchLink><br /><searchLink fieldCode="AR" term="%22Diaz%2C+José+Ángel%22">Diaz, José Ángel</searchLink><br /><searchLink fieldCode="AR" term="%22Feliciangeli%2C+Eduardo%22">Feliciangeli, Eduardo</searchLink><br /><searchLink fieldCode="AR" term="%22Gallego%2C+Javier%22">Gallego, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Llanos%2C+Marta%22">Llanos, Marta</searchLink><br /><searchLink fieldCode="AR" term="%22Segura%2C+Ángel%22">Segura, Ángel</searchLink><br /><searchLink fieldCode="AR" term="%22Vilardell%2C+Felip%22">Vilardell, Felip</searchLink><br /><searchLink fieldCode="AR" term="%22Percovich%2C+Juan+Carlos%22">Percovich, Juan Carlos</searchLink><br /><searchLink fieldCode="AR" term="%22Grande%2C+Enrique%22">Grande, Enrique</searchLink><br /><searchLink fieldCode="AR" term="%22Capdevila%2C+Jaume%22">Capdevila, Jaume</searchLink><br /><searchLink fieldCode="AR" term="%22Valle%2C+Juan+W%2E%22">Valle, Juan W.</searchLink><br /><searchLink fieldCode="AR" term="%22García-carbonero%2C+Rocío%22">García-carbonero, Rocío</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Carmona-bayonas , A , Jiménez-fonseca , P , Lamarca , Á , Barriuso , J , Castaño , Á , Benavent , M , Alonso , V , Riesco-martínez , M D C , Alonso-gordoa , T , Custodio , A , Sánchez Cánovas , M , Hernando Cubero , J , López , C , Lacasta , A , Fernández Montes , A , Marazuela , M , Crespo , G , Escudero , P , Diaz , J Á , Feliciangeli , E , Gallego , J , Llanos , M , Segura , Á , Vilardell .... ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => The University of Manchester: Research Explorer - Publications ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22somatostatin+analogs%22">somatostatin analogs</searchLink><br /><searchLink fieldCode="DE" term="%22lanreotide%22">lanreotide</searchLink><br /><searchLink fieldCode="DE" term="%22neuroendocrine+tumors%22">neuroendocrine tumors</searchLink><br /><searchLink fieldCode="DE" term="%22nomogram%22">nomogram</searchLink><br /><searchLink fieldCode="DE" term="%22octreotide%22">octreotide</searchLink><br /><searchLink fieldCode="DE" term="%22prognostic+model%22">prognostic model</searchLink><br /><searchLink fieldCode="DE" term="%22progression-free+survival%22">progression-free survival</searchLink><br /><searchLink fieldCode="DE" term="%22ResearchInstitutes%5FNetworks%5FBeacons%2Fmcrc%22">ResearchInstitutes_Networks_Beacons/mcrc</searchLink><br /><searchLink fieldCode="DE" term="%22Manchester+Cancer+Research+Centre%22">Manchester Cancer Research Centre</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. PATIENTS AND METHODS We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom). RESULTS We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively. CONCLUSION The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1200/JCO.19.00980 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1200/JCO.19.00980<br />https://research.manchester.ac.uk/en/publications/d2d3b527-1f1d-4af6-996b-0761cc39e363<br />https://pure.manchester.ac.uk/ws/files/121181372/jco.19.00980.pdf ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => info:eu-repo/semantics/openAccess ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.EE077A56 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1200/JCO.19.00980
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => somatostatin analogs
[Type] => general
)
[1] => Array
(
[SubjectFull] => lanreotide
[Type] => general
)
[2] => Array
(
[SubjectFull] => neuroendocrine tumors
[Type] => general
)
[3] => Array
(
[SubjectFull] => nomogram
[Type] => general
)
[4] => Array
(
[SubjectFull] => octreotide
[Type] => general
)
[5] => Array
(
[SubjectFull] => prognostic model
[Type] => general
)
[6] => Array
(
[SubjectFull] => progression-free survival
[Type] => general
)
[7] => Array
(
[SubjectFull] => ResearchInstitutes_Networks_Beacons/mcrc
[Type] => general
)
[8] => Array
(
[SubjectFull] => Manchester Cancer Research Centre
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carmona-bayonas, Alberto
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jiménez-fonseca, Paula
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lamarca, Ángela
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Barriuso, Jorge
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Castaño, Ángel
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Benavent, Marta
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alonso, Vicente
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Riesco-martínez, María Del Carmen
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alonso-gordoa, Teresa
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Custodio, Ana
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sánchez Cánovas, Manuel
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hernando Cubero, Jorge
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => López, Carlos
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lacasta, Adelaida
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fernández Montes, Ana
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marazuela, Mónica
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Crespo, Guillermo
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Escudero, Pilar
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Diaz, José Ángel
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Feliciangeli, Eduardo
)
)
)
[20] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gallego, Javier
)
)
)
[21] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Llanos, Marta
)
)
)
[22] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Segura, Ángel
)
)
)
[23] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vilardell, Felip
)
)
)
[24] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Percovich, Juan Carlos
)
)
)
[25] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Grande, Enrique
)
)
)
[26] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Capdevila, Jaume
)
)
)
[27] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Valle, Juan W.
)
)
)
[28] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => García-carbonero, Rocío
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Carmona-bayonas , A , Jiménez-fonseca , P , Lamarca , Á , Barriuso , J , Castaño , Á , Benavent , M , Alonso , V , Riesco-martínez , M D C , Alonso-gordoa , T , Custodio , A , Sánchez Cánovas , M , Hernando Cubero , J , López , C , Lacasta , A , Fernández Montes , A , Marazuela , M , Crespo , G , Escudero , P , Diaz , J Á , Feliciangeli , E , Gallego , J , Llanos , M , Segura , Á , Vilardell , F , Percovich , J C , Grande , E , Capdevila , J , Valle , J W & García-carbonero , R 2019 , ' Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study ' , Journal of Clinical Oncology , pp. JCO.19.00980 . https://doi.org/10.1200/JCO.19.00980
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |